An animal model of oxaliplatin-induced cold allodynia reveals a crucial role for Nav1.6 in peripheral pain pathways
about
Epigenetic mechanisms of chronic painδ-Conotoxin SuVIA suggests an evolutionary link between ancestral predator defence and the origin of fish-hunting behaviour in carnivorous cone snailsPharmacological characterisation of the highly NaV1.7 selective spider venom peptide Pn3a.Multiple sodium channel isoforms mediate the pathological effects of Pacific ciguatoxin-1.Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy.An approach to identify microRNAs involved in neuropathic pain following a peripheral nerve injury.Cold sensitivity of TRPA1 is unveiled by the prolyl hydroxylation blockade-induced sensitization to ROSLocal knockdown of the NaV1.6 sodium channel reduces pain behaviors, sensory neuron excitability, and sympathetic sprouting in rat models of neuropathic pain.Novel sodium channel antagonists in the treatment of neuropathic pain.The molecular and cellular basis of thermosensation in mammals.Navβ4 regulates fast resurgent sodium currents and excitability in sensory neuronsAntihyperalgesic effect of tetrodotoxin in rat models of persistent muscle pain.Characterization of Endogenous Sodium Channels in the ND7-23 Neuroblastoma Cell Line: Implications for Use as a Heterologous Ion Channel Expression System Suitable for Automated Patch Clamp ScreeningInflammatory and neuropathic cold allodynia are selectively mediated by the neurotrophic factor receptor GFRα3Development of a μO-Conotoxin Analogue with Improved Lipid Membrane Interactions and Potency for the Analgesic Sodium Channel NaV1.8.(S)-lacosamide inhibition of CRMP2 phosphorylation reduces postoperative and neuropathic pain behaviors through distinct classes of sensory neurons identified by constellation pharmacology.A gain-of-function mutation in Nav1.6 in a case of trigeminal neuralgiaThe role of sodium channels in painful diabetic and idiopathic neuropathy.Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain.Pain without nociceptors? Nav1.7-independent pain mechanisms.Local knockdown of Nav1.6 relieves pain behaviors induced by BmK I.FHF2 isoforms differentially regulate Nav1.6-mediated resurgent sodium currents in dorsal root ganglion neurons.Visceral and somatic pain modalities reveal NaV 1.7-independent visceral nociceptive pathways.Analgesic Effects of GpTx-1, PF-04856264 and CNV1014802 in a Mouse Model of NaV1.7-Mediated Pain.Effects of Tetrodotoxin in Mouse Models of Visceral Pain.Comprehensive thermal preference phenotyping in mice using a novel automated circular gradient assay.Platinum-induced neurotoxicity: A review of possible mechanisms.Methods Used to Evaluate Pain Behaviors in Rodents.Analgesic effects of clinically used compounds in novel mouse models of polyneuropathy induced by oxaliplatin and cisplatin.Current View in Platinum Drug Mechanisms of Peripheral Neurotoxicity.Effects of the compounds resveratrol, rutin, quercetin, and quercetin nanoemulsion on oxaliplatin-induced hepatotoxicity and neurotoxicity in mice.Distinct Mechanism of Cysteine Oxidation-Dependent Activation and Cold Sensitization of Human Transient Receptor Potential Ankyrin 1 Channel by High and Low Oxaliplatin.Sodium channels in pain disorders: pathophysiology and prospects for treatment.Multimodal quantitative examination of nerve function in colorectal cancer patients prior to chemotherapy.Sodium channels and pain: from toxins to therapies.Pain-Causing Venom Peptides: Insights into Sensory Neuron Pharmacology.Repeated administration of mirtazapine attenuates oxaliplatin-induced mechanical allodynia and spinal NR2B up-regulation in rats.Conditional knockout of NaV1.6 in adult mice ameliorates neuropathic pain.The Na1.7 Channel Subtype as an Antinociceptive Target for Spider Toxins in Adult Dorsal Root Ganglia Neurons
P2860
Q27023688-5D474798-A3D2-4464-AE20-199B83A94CE8Q27329762-596FEC6E-120A-482C-8F53-01EB4ABF7266Q30835612-869E1E30-0ABE-4151-B6FC-D89613EF21AEQ30839530-2AE07F44-7FCD-46E2-B141-D2FE7BB2514FQ33744706-F0A232EF-E0EC-4D1A-B2BA-C841DE95E211Q34107081-9C48E66F-78F5-44F1-B486-6C86C239875CQ34540308-874A3306-52EB-48E0-B37B-472A54A4A3A6Q35205500-CE0E5AE9-0345-460F-BB45-7C435ED076A0Q35843983-396D8C81-9CE5-46DB-871F-8FBE52D26FC0Q35883351-05464A5B-8C1A-4B79-AEE6-57977CE99A5FQ36091952-3A66476E-2290-4843-B3A5-53434620527CQ36372168-031D5A25-0496-46FC-B066-6611C7C145E9Q36707638-DFA4C5B9-FF5F-47FF-A291-7C7D38B6AF44Q36831604-E2A52040-CC9D-4A66-B2F0-688929E88EF8Q36941125-C7BBC11A-18C8-4A03-AB63-CB82892EB168Q37074848-6288FBB1-8C20-4260-9B53-6EEB6EE59590Q37256342-48051294-44E9-48C1-BB06-E79B67181B4BQ38241746-92D360E4-2CDB-4F98-BDF6-05E38B867D98Q38264622-5FBF5CE2-8BC8-41E9-AAEE-572419C1DC38Q38552593-9558B03F-4943-4A0E-95A9-1C1C2223D898Q38706503-A3DC21BD-B4FD-4E51-A693-0248784AF845Q38725114-0FCD0422-BD57-4726-BEDB-7E830FCB2ED1Q39010857-39F58479-D88C-4AAB-A283-0F263BA19413Q39587472-3925ED38-7083-4BF1-96F0-5C205BFA177CQ41045838-4C1B41F7-226B-407A-A5A5-244C5E508268Q41198828-EEBB9D7A-7B7E-47DE-A2B0-71A4734A9DB8Q41374593-E96606C5-D190-404E-92D7-5D1638E18A27Q41440352-07750FE5-7C43-4566-9BD9-F247D9969040Q41852990-F37455E4-DD08-4FA3-B270-0B7F0459554DQ42361420-C4D93E48-63D5-4C70-9D71-C5AEEC3E9CC9Q45357979-56D3BD43-D7F2-4FA7-A341-556A3F5C968EQ46256708-997903A1-44CB-449D-A508-B2458A2ABB13Q47959907-4DD97CF2-0247-4C9A-8207-9CF872A1FB22Q48020601-D420A776-4479-4CD9-B48F-03C2D4E475AAQ48337085-5354D3B2-E3FF-4D7D-9E74-73F2E0255F6CQ48343647-296DE511-8394-4B1F-B6AA-40AFF0169DA6Q50850838-529B2CFB-594C-4775-94B5-67FD80F179D6Q52678220-E09C8755-16F7-4251-A281-9D99BA842585Q58764681-FB99A1D1-03A8-4822-946F-8CC73239772A
P2860
An animal model of oxaliplatin-induced cold allodynia reveals a crucial role for Nav1.6 in peripheral pain pathways
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 May 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
An animal model of oxaliplatin ...... .6 in peripheral pain pathways
@en
An animal model of oxaliplatin ...... 6 in peripheral pain pathways.
@nl
type
label
An animal model of oxaliplatin ...... .6 in peripheral pain pathways
@en
An animal model of oxaliplatin ...... 6 in peripheral pain pathways.
@nl
prefLabel
An animal model of oxaliplatin ...... .6 in peripheral pain pathways
@en
An animal model of oxaliplatin ...... 6 in peripheral pain pathways.
@nl
P2860
P50
P1433
P1476
An animal model of oxaliplatin ...... .6 in peripheral pain pathways
@en
P2093
Andrej A Romanovsky
Peter J Cabot
P2860
P304
P356
10.1016/J.PAIN.2013.05.032
P407
P577
2013-05-24T00:00:00Z